Clinical trials: Rejection Heart Transplant
Heart Transplant Rejection
Prospera Test Evaluation in Cardiac Transplant (ProTECT)
The ProTECT registry is an observational longitudinal, multi-center study observing patients undergoing heart transplant for whom Prospera testing is part of routine clinical care, who are enrolled within 60 days of heart…
- Trial name
- ProTECT (NCT05205551)
- Where
- United States
- Volunteers
- 411 people
- Sponsor
- Natera, Inc.
Cardiac Allograft Vasculopathy, Acute Cellular Graft Rejection
Cardiac Mitochondrial Function After Heart Transplantation
Studies have shown that cardiac function is affected immediately after heart transplantation (HTx), but seems to recover to some extent over the first year.
- Conditions
- Cardiac Allograft Vasculopathy, Acute Cellular Graft Rejection, Primary Graft Failure, Mitochondrial Function
- Trial name
- ENERGY-HTX (NCT04105803)
- Where
- Denmark
- Volunteers
- 64 people
- Sponsor
- University of Aarhus
Pediatric Heart Transplantation, Immunosuppression
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
The TEAMMATE Trial will enroll 210 pediatric heart transplant patients from 25 centers at 6 months post-transplant and follow each patient for 2.5 years.
- Conditions
- Pediatric Heart Transplantation, Immunosuppression, Chronic Kidney Diseases, Cardiac Allograft Vasculopathy
- Trial name
- TEAMMATE (NCT03386539)
- Testing
- Everolimus, Tacrolimus, Mycophenolate Mofetil
- Where
- 25 sites in United States
- Volunteers
- 211 people
- Sponsor
- Boston Children's Hospital
Heart Transplantation, Graft Rejection
ZeroHeart Biopsy - Prediction of Deceased Donor Heart Transplant Performance From Organ Donors Using Pre-Transplant Biopsies - A Pilot Study
The goal of this observational study is to evaluate whether molecular analysis of donor heart biopsies taken at the time of organ removal ("Time Zero") can help predict the future function and rejection risk of the transplanted…
- Conditions
- Heart Transplantation, Graft Rejection, Myocardial Injury, Organ Preservation
- Trial name
- ZeroHeart (NCT06982404)
- Testing
- Time Zero Donor Heart Biopsy for Molecular Analysis
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Medical University of Vienna
Heart Transplant Failure and Rejection
Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant
Immunosuppressive therapy is required to prevent organ rejection, however, dosing of immunosuppressive agents is complicated by patient-specific differences impacting the body's absorption and elimination of these agents.
- Trial name
- NCT04380311
- Testing
- Tacrolimus Dosing Support Tool
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- University of Utah
Graft Rejection, Heart Diseases
IMAGE: A Comparison of AlloMap Molecular Testing and Traditional Biopsy-based Surveillance for Heart Transplant Rejection
This study is designed to evaluate the safety and efficacy of a leukocyte gene expression profiling method in the monitoring of asymptomatic heart transplant patients for acute rejection.
- Trial name
- NCT00351559
- Testing
- AlloMap molecular expression testing, Right ventricular endomyocardial biopsy
- Where
- 13 sites in United States
- Volunteers
- 629 people
- Sponsor
- XDx
Heart Transplant Rejection
Cardiac Transplant Metabolomics With and Without Rejection
Patient who received a heart transplant may develop organ rejection. Currently, an invasive biopsy of the heart needs to be performed to diagnose rejection.
- Trial name
- ANTIPARTICLE (NCT05772442)
- Testing
- Extra blood samples (5-10 mL) drawn
- Volunteers
- 100 people
- Sponsor
- Western University, Canada
Cardiac Transplantation
Non Invasive Detection of Cardiac Allograft Rejection by Circulating microRNAs
The purpose of this study is to evaluate the level of expression of 4 circulating microRNAs in the serum using RT-PCR. A pilote study with cardiac transplant patients has shown that expression of these microRNAs could…
- Trial name
- MIRRACLE (NCT02672683)
- Where
- France
- Volunteers
- 461 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
CMV Viremia, Heart Transplant Infection
Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.
- Conditions
- CMV Viremia, Heart Transplant Infection, Heart Transplant Failure and Rejection
- Trial name
- VALET-CMV (NCT07079735)
- Testing
- Letermovir, Valganciclovir
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Columbia University
Heart Transplant Failure and Rejection
Donor-Derived Cell-free DNA to DETect REjection in Cardiac Transplantation
The study objective is to demonstrate that rejection surveillance of heart transplant recipients with Prospera dd-cfDNA is non-inferior to rejection surveillance with endomyocardial biopsy and histology in the first…
- Trial name
- DETECT (NCT05081739)
- Testing
- Prospera Transplant Assessment, Endomyocardial biopsy
- Sponsor
- Natera, Inc.
Heart Transplant, Acute Graft Rejection
Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction
The investigators will use cardiac MRI to measure the myocardial perfusion reserve and amount of myocardial edema and fibrosis in heart-transplant patients with nonspecific allograft dysfunction in contrast to those with normal…
- Conditions
- Heart Transplant, Acute Graft Rejection, Chronic Graft Rejection
- Trial name
- NCT02597543
- Testing
- Regadenoson, Gadolinium, Cardiac MRI
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Paul Kim
Heart Transplant Failure and Rejection
Impact of Donor and Recipient ST2 / IL-33 Pathway After Heart Transplantation
Evaluate the association between donor soluble protein ST2 (sST2) serum levels and 30-day recipient mortality in order to improve graft screening.
- Trial name
- ISIDORE (NCT03050892)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Heart Transplant Rejection, Immune Suppression
Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients
We will conduct a two-group randomized controlled trial to examine the eMocha DOT intervention with pediatric HT recipients.In this population, medication nonadherence remains a primary cause of late acute rejection (LAR)…
- Conditions
- Heart Transplant Rejection, Immune Suppression, Pediatric Heart Transplant, Medication Nonadherence
- Trial name
- NCT05732779
- Testing
- DOT intervention
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of Florida